secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2026-05-13T20:07:44+00:00
Accession:  0001055726-26-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA
--------------------------------------------------------------------------------

- Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.
- Revenue not reported (pre-revenue biotech); R&D spend $14.1M (-12% YoY), G&A $7.9M (-12%).
- Cash & equivalents $37.7M at Mar 31, plus $16M from April offering; expects ops into Q1 2027.
- FDA reviewing INO-3107 BLA under accelerated approval; PDUFA date Oct 30, 2026.
- Collaboration with Akeso to test INO-5412 + cadonilimab in GBM in Dana-Farber INSIGhT trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/0001055726-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001055726-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer